Safety and Performance of a Novel Defibrillation Lead for LBBAP: Primary Results of LEADR LBBAP

Authors, Journal, Affiliations, Type, DOI

Overview

LEADR LBBAP is the first prospective trial of the 4.7-F lumenless OmniaSecure defibrillation lead when implanted for left bundle branch area pacing. Of 307 implant attempts, 293 (95.4%) met the protocol definition of success; all 162 patients in the primary defibrillation cohort were successfully defibrillated at implant (95% CI 97.7–100), and freedom from lead-related major complications at 3 months was 97.9% (95% CI 95.8–100). Electrical parameters were stable through a mean follow-up of 2.6 months, with no lead fractures or oversensing-related adverse events. The trial supports a single-lead strategy that combines defibrillation with LBBAP and provides the short-term safety and efficacy basis for placing this lead in the conduction system rather than the standard right ventricular position. The later final-results report extends follow-up to 12 months (sources/leadr-lbbap-hrs-2025); the right-ventricular LEADR trial provides 3-year data for the same lead platform (sources/leadr-final-circep-2026).

Keywords

Conduction system pacing; Left bundle branch area pacing; Defibrillation lead; Cardiac resynchronization; Defibrillation efficacy

Key Takeaways

Study design and population

Implant procedure and LBBAP confirmation

Primary efficacy: defibrillation at implant

Electrical and sensing performance

Primary safety

LOT-CRT and QRS outcomes

Interpretation

Limitations of the document

Key Concepts Mentioned

Key Entities Mentioned

Wiki Pages Updated